Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1975) 1975
Book Chapter (24) 24
Magazine Article (11) 11
Dissertation (6) 6
Conference Proceeding (5) 5
Government Document (3) 3
Book / eBook (1) 1
Publication (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1400) 1400
life sciences & biomedicine (1344) 1344
humans (1317) 1317
sofosbuvir (1261) 1261
hepatitis c (914) 914
antiviral agents - therapeutic use (845) 845
hepatitis c, chronic - drug therapy (824) 824
hepatitis c virus (751) 751
male (731) 731
female (660) 660
middle aged (651) 651
drug therapy, combination (583) 583
sofosbuvir - therapeutic use (583) 583
gastroenterology & hepatology (563) 563
hepatitis (558) 558
hepacivirus - genetics (534) 534
genotype (511) 511
treatment outcome (480) 480
ribavirin (428) 428
interferon (401) 401
aged (390) 390
adult (387) 387
ribavirin - therapeutic use (367) 367
hepatitis c - drug therapy (362) 362
antiviral agents - administration & dosage (361) 361
antiviral agents (352) 352
uridine monophosphate - analogs & derivatives (330) 330
hepacivirus - drug effects (316) 316
antiviral agents - adverse effects (312) 312
sofosbuvir - administration & dosage (296) 296
infectious diseases (291) 291
pharmacology & pharmacy (290) 290
hepatitis c, chronic - virology (271) 271
sustained virologic response (270) 270
health aspects (269) 269
drug therapy (263) 263
patients (262) 262
ledipasvir (261) 261
liver (257) 257
care and treatment (241) 241
uridine monophosphate - therapeutic use (236) 236
daclatasvir (234) 234
genotype & phenotype (234) 234
infections (234) 234
sofosbuvir - adverse effects (226) 226
liver cirrhosis (221) 221
cirrhosis (220) 220
benzimidazoles - therapeutic use (208) 208
analysis (202) 202
simeprevir (201) 201
fluorenes - therapeutic use (195) 195
hcv (186) 186
genotypes (183) 183
ribavirin - administration & dosage (179) 179
viruses (178) 178
hepatitis c, chronic - complications (177) 177
abridged index medicus (164) 164
virology (163) 163
general & internal medicine (160) 160
medicine, general & internal (159) 159
virus diseases (155) 155
imidazoles - therapeutic use (154) 154
genetic aspects (152) 152
biological response modifiers (150) 150
liver transplantation (142) 142
retrospective studies (141) 141
hepatology (136) 136
antiviral agents - pharmacology (135) 135
transplantation (133) 133
viral load (132) 132
gastroenterology and hepatology (127) 127
direct-acting antivirals (125) 125
young adult (125) 125
carbamates - therapeutic use (123) 123
microbiology (120) 120
sulfonamides - therapeutic use (119) 119
hepatitis c - virology (118) 118
drug combinations (114) 114
chronic hepatitis c (113) 113
clinical trials (112) 112
benzimidazoles - administration & dosage (111) 111
liver cirrhosis - virology (111) 111
recurrence (111) 111
liver diseases (109) 109
fluorenes - administration & dosage (108) 108
medical research (108) 108
ribavirin - adverse effects (108) 108
liver cirrhosis - drug therapy (107) 107
antiviral agents - economics (106) 106
hepacivirus (106) 106
immunology (106) 106
chronic infection (105) 105
aged, 80 and over (102) 102
prospective studies (101) 101
research (101) 101
viral nonstructural proteins - antagonists & inhibitors (100) 100
hepacivirus - isolation & purification (97) 97
medicine & public health (97) 97
simeprevir - therapeutic use (97) 97
digestive system diseases (94) 94
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1896) 1896
Korean (63) 63
German (28) 28
Portuguese (16) 16
French (12) 12
Spanish (12) 12
Chinese (9) 9
Czech (6) 6
Japanese (6) 6
Hungarian (5) 5
Russian (4) 4
Dutch (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
by Svarovskaia, Evguenia S and Gane, Edward and Dvory-Sobol, Hadas and Martin, Ross and Doehle, Brian and Hedskog, Charlotte and Jacobson, Ira M and Nelson, David R and Lawitz, Eric and Brainard, Diana M and McHutchison, John G and Miller, Michael D and Mo, Hongmei
The Journal of infectious diseases, ISSN 0022-1899, 04/2016, Volume 213, Issue 8, pp. 1240 - 1247
sofosbuvir | L159F | V321A | direct-acting antivirals | resistance | HCV NS5B sofosbuvir resistance-associated variants | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Hepacivirus - genetics | Sequence Analysis, RNA | Molecular Epidemiology | Antiviral Agents - adverse effects | Hepatitis C - epidemiology | Hepatitis C - virology | Drug Resistance, Viral - drug effects | High-Throughput Nucleotide Sequencing | Sofosbuvir - adverse effects | Genotype | Care and treatment | Interferon | Dosage and administration | Research | Hepatitis C | Index Medicus | Abridged Index Medicus | Major and Brief Reports | HCV NS5B sofosbuvir resistance–associated variants
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials
by Grebely, Jason and Dore, Gregory J and Zeuzem, Stefan and Aspinall, Richard J and Fox, Raymond and Han, Lingling and McNally, John and Osinusi, Anu and Brainard, Diana M and Subramanian, G. Mani and Natha, Macky and Foster, Graham R and Mangia, Alessandra and Sulkowski, Mark and Feld, Jordan J
Clinical infectious diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1479 - 1481
OST | HCV | Velpatasvir | Sofosbuvir | PWID | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Adult | Female | Opiate Substitution Treatment | Sofosbuvir - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Data Interpretation, Statistical | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis C, Chronic - blood | Medication Adherence | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Carbamates - adverse effects | Sustained Virologic Response | Carbamates - therapeutic use | Hepatitis C, Chronic - genetics | Treatment outcome | Hepatitis C | Drug therapy | Analysis | Prescription drugs | Hepatitis | Substance abuse treatment | Safety | Index Medicus | sofosbuvir | Brief Reports | velpatasvir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
by Elfiky, Abdo A
Life sciences (1973), ISSN 0024-3205, 05/2020, Volume 248, pp. 117477 - 6
COVID-19 | Structural bioinformatics | Wuhan coronavirus | Nucleotide inhibitors | RdRp | Docking | Sofosbuvir | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Guanosine Monophosphate - chemistry | Uridine Triphosphate - metabolism | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | RNA Replicase - metabolism | Adenosine Monophosphate - chemistry | Betacoronavirus - enzymology | Sofosbuvir - metabolism | Alanine - chemistry | Alphacoronavirus - enzymology | RNA Replicase - antagonists & inhibitors | Guanosine Triphosphate - metabolism | Antiviral Agents - metabolism | Viral Proteins - metabolism | Alanine - analogs & derivatives | Thermodynamics | Alphacoronavirus - genetics | Antiviral Agents - chemistry | Guanosine Monophosphate - analogs & derivatives | Guanosine Triphosphate - chemistry | Protein Interaction Domains and Motifs | Amino Acid Sequence | Protein Conformation, alpha-Helical | Catalytic Domain | Computational Biology - methods | Adenosine Monophosphate - metabolism | Viral Proteins - chemistry | Alanine - metabolism | Viral Proteins - antagonists & inhibitors | Ribavirin - metabolism | Uridine Triphosphate - chemistry | Ribavirin - chemistry | Sequence Homology, Amino Acid | Sequence Alignment | Coronavirus Infections - virology | Protein Conformation, beta-Strand | Guanosine Monophosphate - metabolism | RNA Replicase - chemistry | Adenosine Monophosphate - analogs & derivatives | Drug Repositioning - methods | Protein Binding | Molecular Docking Simulation | Betacoronavirus - genetics | Pneumonia, Viral - virology | Sofosbuvir - chemistry | Drugs | Disease transmission | Nucleotide sequence | Viral diseases | Fatalities | Coronaviruses | RNA polymerase | Nucleotides | DNA-directed RNA polymerase | Ribavirin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text 12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
by Luetkemeyer, Anne F and McDonald, Cheryl and Ramgopal, Moti and Noviello, Stephanie and Bhore, Rafia and Ackerman, Peter
Clinical infectious diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1489 - 1496
HIV-HCV | sofosbuvir | coinfection | antiretroviral therapy | daclatasvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | HIV-1 | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Viral Load | Young Adult | Adult | Female | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Drug Therapy, Combination | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | HIV Infections - virology | Imidazoles - adverse effects | Antiviral Agents - administration & dosage | Coinfection - virology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Hepacivirus | Antiviral agents | Hepatitis | Usage | Care and treatment | Comorbidity | Analysis | Antiretroviral drugs | Viruses | Drug therapy | Product safety | Human immunodeficiency virus--HIV | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
by Jacobson, Ira M and Lawitz, Eric and Gane, Edward J and Willems, Bernard E and Ruane, Peter J and Nahass, Ronald G and Borgia, Sergio M and Shafran, Stephen D and Workowski, Kimberly A and Pearlman, Brian and Hyland, Robert H and Stamm, Luisa M and Svarovskaia, Evguenia and Dvory-Sobol, Hadas and Zhu, Yanni and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Bräu, Norbert and Berg, Thomas and Agarwal, Kosh and Bhandari, Bal Raj and Davis, Mitchell and Feld, Jordan J and Dore, Gregory J and Stedman, Catherine A.M and Thompson, Alexander J and Asselah, Tarik and Roberts, Stuart K and Foster, Graham R
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
by Walsh, C. E and Workowski, K and Terrault, N. A and Sax, P. E and Cohen, A and Bowlus, C. L and Kim, A. Y and Hyland, R. H and Han, B and Wang, J and Stamm, L. M and Brainard, D. M and McHutchison, J. G and Drygalski, A and Rhame, F and Fried, M. W and Kouides, P and Balba, G and Reddy, K. R
Haemophilia : the official journal of the World Federation of Hemophilia, ISSN 1351-8216, 03/2017, Volume 23, Issue 2, pp. 198 - 206
sofosbuvir | hepatitis C virus | NS5A inhibitor | ribavirin | NS5B inhibitor | ledipasvir–sofosbuvir fixed‐dose combination | ledipasvir–sofosbuvir fixed-dose combination | Life Sciences & Biomedicine | Hematology | Science & Technology | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Fluorenes - therapeutic use | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Young Adult | Benzimidazoles - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Aged | Drug Combinations | Benzimidazoles - therapeutic use | Complications and side effects | Care and treatment | Mortality | Hemophilia | Blood diseases | Hepatitis C | Hepatitis C virus | Liver cirrhosis | Ribavirin | Headache | Liver | Diarrhea | Chronic infection | Fatigue | Infections | Nausea | Bleeding | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Proton Pump Inhibitor (PPI) Therapy Does Not Affect SVR Rates Among Patients Treated With Ledipasvir/Sofosbuvir Combination Therapy
: 954
by Marshall, Caitlin M and Peace, Danielle and Henderson, Phillip K and Herrera, Jorge
The American journal of gastroenterology, ISSN 0002-9270, 10/2017, Volume 112, p. S535
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The FDA-approved drug sofosbuvir inhibits Zika virus infection
by Bullard-Feibelman, Kristen M and Govero, Jennifer and Zhu, Zhe and Salazar, Vanessa and Veselinovic, Milena and Diamond, Michael S and Geiss, Brian J
Antiviral research, ISSN 0166-3542, 01/2017, Volume 137, pp. 134 - 140
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Virology | Sofosbuvir - therapeutic use | Cell Line | Zika Virus Infection - drug therapy | Antiviral Agents - pharmacology | Sofosbuvir - pharmacology | Administration, Oral | Antiviral Agents - therapeutic use | United States | Humans | Zika Virus - drug effects | Drug Approval | Zika Virus Infection - virology | Animals | Sofosbuvir - administration & dosage | Mice | Drug Evaluation, Preclinical | United States Food and Drug Administration | Antiviral agents | Medical colleges | Genetic disorders | Microbiology | Guillain-Barre syndrome | Birth defects | Drug approval | Virus diseases | Prevention | Stem cell research | Hepatitis | Immunotherapy | Stem cells | Drug therapy | Hepatitis C virus | Health aspects | Biomedical engineering | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir
by Jeffrey M. Collins and Kara Loren Raphael and Charles Terry and Emily J. Cartwright and Angana Pillai and Frank A. Anania and Monica M. Farley
Clinical infectious diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1304 - 1306
BRIEF REPORTS | Simeprevir | HBV/HCV coinfection | Acute hepatitis | HBV reactivation | Sofosbuvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Sofosbuvir - therapeutic use | Coinfection | Administration, Oral | Antiviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Hepatitis B - virology | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis B virus - physiology | Simeprevir - therapeutic use | Hepatitis B - complications | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Drug Therapy, Combination | Hepatitis | Care and treatment | Research | Hepatitis C virus | Disease prevention | Infectious diseases | Antibiotics | Drug therapy | Patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus?
by Ghobrial, Carolyne and Sobhy, Rodina and Mogahed, Engy and Abdullatif, Hala and El-Karaksy, Hanaa
Digestive and liver disease, ISSN 1590-8658, 02/2019, Volume 51, Issue 2, pp. 258 - 262
ECG | Bradycardia | HCV | Sofosbuvir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4
by Doss, Wahid and Shiha, Gamal and Hassany, Mohamed and Soliman, Reham and Fouad, Rabab and Khairy, Marwa and Samir, Waleed and Hammad, Radi and Kersey, Kathryn and Jiang, Deyuan and Doehle, Brian and Knox, Steven J and Massetto, Benedetta and McHutchison, John G and Esmat, Gamal
Journal of hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 3, pp. 581 - 585
Gastroenterology and Hepatology | Antiviral agents | Hepatitis C | Polymerase inhibitor | Sofosbuvir | Egypt | Genotype 4 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Sofosbuvir - adverse effects | Drug Therapy, Combination | Care and treatment | Genetic aspects | Hepatitis C virus | Health aspects | Ribavirin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
by Ruane, Peter J and Ain, Dani and Stryker, Richard and Meshrekey, Raymond and Soliman, Mina and Wolfe, Peter R and Riad, Joseph and Mikhail, Sameh and Kersey, Kathryn and Jiang, Deyuan and Massetto, Benedetta and Doehle, Brian and Kirby, Brian J and Knox, Steven J and McHutchison, John G and Symonds, William T
Journal of hepatology, ISSN 0168-8278, 2014, Volume 62, Issue 5, pp. 1040 - 1046
Gastroenterology and Hepatology | Hepatitis C virus | Direct-acting antiviral | Egyptian | Sofosbuvir | Interferon-free therapy | Genotype 4 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | United States | Humans | Middle Aged | Egypt | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA Replicase - antagonists & inhibitors | Hepatitis C, Chronic - ethnology | Ribavirin - administration & dosage | Adult | Female | Sofosbuvir - adverse effects | Hepacivirus - drug effects | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Viral Load - drug effects | Viral Load - methods | Viral Nonstructural Proteins - antagonists & inhibitors | Virus diseases | Care and treatment | Genetic aspects | Health aspects | Ribavirin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights